Markets
LLY

Shire (SHPG) Gets CRL for Dry Eye Disease Drug from FDA

Shire plcSHPG provided an update on its plans to respond to a complete response letter (CRL) served by the FDA for the company's new drug application (NDA) for lifitegrast. The company is looking to get lifitegrast approved for the treatment of the signs and symptoms of dry eye disease in adults.

We remind investors that late last week the company had received a CRL for its NDA for lifitegrast from the FDA. The agency asked Shire to conduct an additional study on the candidate. Additionally, the FDA demanded further information from the company related to the quality of the candidate.

The company stated that it has already completed a phase III study (OPUS-3) evaluating the efficacy and safety of lifitegrast, with top-line data expected by year end. If data from the study is positive, it will form the basis of the company's response to the CRL. Shire intends to resubmit its NDA for liftegrast in the first quarter of 2016. The company said that it remains on track for the planned launch of lifitegrast in 2016 (if approved).

Our Take

The FDA's denial to approve Shire's NDA for liftegrast is a definite setback for the company. Shire highly depends on data from the OPUS-3 study for the approval of liftegrast, going forward.

We expect investor focus to remain on pipeline and regulatory updates on liftegrast.

Meanwhile, we remind note that Shire is well-known for its attention deficit hyperactivity disorder ADHD portfolio which includes drugs like Intuniv, Vyvanse and Adderall XR. Other drugs approved for ADHD include Eli Lilly and Company's LLY Strattera, Johnson & Johnson's (JNJ) Concerta and Novartis' NVS Ritalin.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

LILLY ELI & CO (LLY): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

ALCOBRA LTD (ADHD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LLY NVS

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More